Lear has been appointed by the European Commission to carry out an ex-post evaluation of EU competition enforcement looking at acquisitions of innovative competitors in the pharmaceutical sector that have led to the discontinuation of overlapping drug research and development projects to the detriment of future competition (“killer acquisitions”).
The study will assess the actual scope and characteristics of the phenomenon of “killer acquisitions” in the pharmaceutical sector and will devise a methodology that will enable the Commission to identify such instances in the future. In addition, the project will evaluate how well the Commission’s substantive merger assessment dealt with “killer acquisitions”, as well as the legal framework within which the Commission operates. On this project, Lear is supported by a team of academics, including Prof. Carmine Ornaghi (University of Southampton) and Prof. Anna Rita Bennato (Loughborough University), and a team of experts in the pharmaceutical sector.
See here for the full list of DG COMP tenders.